middle.news
MVP’s FY25 Surge: Revenue Up 18%, Eyes on Penthrox Volume Growth
9:14pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
MVP’s FY25 Surge: Revenue Up 18%, Eyes on Penthrox Volume Growth
9:14pm on Friday 29th of August, 2025 AEST
Key Points
Group revenue rises 18% to $39.1 million
Underlying EBIT loss narrows dramatically to near breakeven
43% volume growth in Australian hospital segment
Paediatric indication approved in Europe with UK and EU approvals pending
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Medical Developments International (ASX:MVP)
OPEN ARTICLE